Skip to main content
. Author manuscript; available in PMC: 2020 Oct 20.
Published in final edited form as: Heart. 2020 Mar 6;106(21):1679–1685. doi: 10.1136/heartjnl-2019-316065

Table 3.

Hazard ratios and 95% confidence intervals of cardiovascular outcomes by income category and adjusted for covariates in cohort with AF

Income
<$40K $40–59K $60–74K $75–99K ≥$100K p-value for trend
Heart Failure*
 Model 1 1.41 (1.28, 1.55) 1.30 (1.17, 1.44) 1.22 (1.08, 1.38) 1.18 (1.05, 1.33) 1 (ref) <0.0001
 Model 2 1.19 (1.07, 1.32) 1.14 (1.02, 1.28) 1.11 (0.98, 1.26) 1.10 (0.97, 1.24) 1 (ref) 0.03
 Model 3 1.17 (1.05, 1.30) 1.13 (1.01, 1.26) 1.10 (0.97, 1.25) 1.09 (0.97, 1.23) 1 (ref) 0.05
Myocardial Infarction
 Model 1 1.35 (1.14, 1.60) 1.28 (1.07, 1.54) 1.18 (0.95, 1.46) 1.10 (0.89, 1.36) 1 (ref) 0.005
 Model 2 1.18 (0.98, 1.42) 1.16 (0.96, 1.41) 1.09 (0.87, 1.36) 1.05 (0.85, 1.30) 1 (ref) 0.42
 Model 3 1.18 (0.98, 1.41) 1.15 (0.95, 1.40) 1.09 (0.87, 1.36) 1.05 (0.84, 1.30) 1 (ref) 0.46
Ischemic stroke
 Model 1 1.06 (0.95, 1.18) 0.97 (0.86, 1.1) 0.99 (0.86, 1.14) 1.00 (0.87, 1.15) 1 (ref) 0.36
 Model 2 0.98 (0.87, 1.11) 0.92 (0.81, 1.04) 0.95 (0.82, 1.09) 0.97 (0.84, 1.11) 1 (ref) 0.62
 Model 3 0.99 (0.88, 1.12) 0.92 (0.81, 1.05) 0.95 (0.82, 1.1) 0.97 (0.84, 1.12) 1 (ref) 0.61
*

Prevalent heart failure was excluded from Model 3 when calculating incident heart failure

Prevalent coronary heart disease was excluded from Model 3 when calculating incident myocardial infarction

Prevalent ischemic stroke was excluded from Model 3 when calculating incident ischemic stroke

Model 1 adjusted for baseline age, sex, and race.

Model 2 adjusted for baseline age, sex, race, education, hypertension, diabetes, and prevalent ischemic stroke, prevalent coronary heart disease, and prevalent heart failure.

Model 3 adjusted for baseline age, sex, race, education, hypertension, diabetes, prevalent ischemic stroke, prevalent coronary heart disease, prevalent heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and oral anticoagulant use.